Sutimlimab is a very-high-cost Part B biologic in a tiny population — economics, not competition, is the central payer question in CAD.
Sutimlimab (Enjaymo) is administered as a weight-based intravenous infusion every two weeks and therefore routes through the Medicare Part B medical benefit as a physician-administered biologic (buy-and-bill), rather than the Part D pharmacy benefit. At a wholesale acquisition cost reported around $1,800 per 1,100-mg vial, annual therapy runs roughly $259,000–$302,000 per patient depending on body weight, placing CAD among the higher per-patient-cost rare-disease indications despite a prevalent US population of only a few thousand patients.
Because sutimlimab is the only FDA-approved CAD therapy and competes against inexpensive off-label rituximab, payers manage it through prior authorization and site-of-care rather than formulary competition. A peer-reviewed US cost-effectiveness analysis concluded that sutimlimab is not cost-effective at its current price, requiring roughly an 80% price reduction, or a capped treatment duration near 1.5 years, to meet standard value benchmarks — a finding payers can use to justify tight utilization management. CAD has not been the subject of a formal ICER review, so this academic cost-effectiveness evidence is the primary HTA reference point.
US CAD payer & access summary — sutimlimab, 2026
| Dimension | Sutimlimab (Enjaymo) |
|---|---|
| Benefit routing | Medicare Part B — IV physician-administered biologic (buy-and-bill); commercial medical benefit |
| Annual cost of therapy | ~$259,000–$302,000 per patient/year (weight-dependent) at reported WAC ~$1,800 per 1,100-mg vial |
| Administration | IV infusion, weight-based, every 2 weeks — ongoing (hemolysis recurs on cessation) |
| Prior authorization | Confirmed CAD diagnosis, symptomatic hemolytic anemia / transfusion need, hematologist prescriber; meningococcal & encapsulated-organism vaccination |
| HTA / cost-effectiveness | No formal ICER review; peer-reviewed US analysis finds it not cost-effective without ~80% price cut or ≤1.5-yr use |
| Population | Small — order-of-magnitude ~5,000 US prevalent patients; limits total budget impact |
Sources: FDA Drugs@FDA (sutimlimab / Enjaymo, BLA761164, Recordati Rare Diseases); WAC and annual cost per Berentsen, Immunotherapy 2022; cost-effectiveness per American Journal of Hematology 2024 (PMID 38733355); Medicare Part B benefit classification. CARDINAL: NEJM 2021 (PMID 33826820); CADENZA: Eur J Haematol 2022 (PMID 36403132).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Part B medical-benefit (buy-and-bill) routing for the IV infusion • Site-of-care (hospital outpatient vs infusion center) economics • Patient out-of-pocket exposure and dual-eligible dynamics • Contrast with an oral / self-administered Part D pathway
Delivers
- • Diagnosis confirmation (CAD vs warm AIHA vs CAS) as a PA gate • Transfusion history / symptomatic hemolytic anemia thresholds • Hematologist prescriber and meningococcal-vaccination requirements • Step-through off-label rituximab considerations
Delivers
- • Published US cost-effectiveness findings and the price-reduction threshold • Absence of a formal ICER review and its implications • Budget-impact logic in a few-thousand-patient indication • Outcomes-based or duration-capped contracting options
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Sutimlimab routes through Medicare Part B as a physician-administered buy-and-bill biologic rather than the Part D pharmacy benefit
- As the only FDA-approved CAD therapy, sutimlimab is managed through prior authorization and site-of-care controls rather than formulary competition
- At a reported WAC of roughly $1,800 per 1,100-mg vial, annual sutimlimab therapy runs $259,000–$302,000 per patient depending on body weight
- Why CAD ranks among the higher per-patient-cost rare-disease indications despite its prevalent US population of only a few thousand patients
- Weight-based IV infusion every two weeks, administered indefinitely since hemolysis recurs on cessation, anchors the buy-and-bill site-of-care economics
- How Part B medical-benefit routing shapes patient out-of-pocket exposure differently than a Part D pharmacy-benefit drug would
- Prior authorization requires a confirmed CAD diagnosis, symptomatic hemolytic anemia or transfusion need, and prescription by a hematologist
- Meningococcal and other encapsulated-organism vaccination requirements sit alongside diagnostic confirmation as utilization-management gates
- A peer-reviewed US cost-effectiveness analysis found sutimlimab is not cost-effective at its current price, requiring roughly an 80% price reduction to meet standard value benchmarks
- CAD has not been the subject of a formal ICER review, leaving this academic cost-effectiveness analysis as the primary HTA reference point payers use
- A prevalent US population of only around 5,000 patients caps total budget impact even at $259K–$302K per patient per year
- A capped treatment duration near 1.5 years is the cost-effectiveness analysis's alternative to an 80% price cut, an option payers could use in contracting
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary sources: regulatory databases, peer-reviewed literature, and live payer and HTA documentation, not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Cold Agglutinin Disease Payer & HTA sources: FDA Drugs@FDA and the sutimlimab label, published pricing and annual-cost data (Immunotherapy 2022), the peer-reviewed US cost-effectiveness analysis (Am J Hematol 2024, PMID 38733355), US epidemiology for budget-impact context (PLoS One 2025, PMID 40570006), and current commercial and Medicare coverage and prior-authorization policies.
- Sutimlimab Part B routing verified against CMS drug classification for physician-administered IV biologics
- Annual cost of therapy verified against published pricing data (Immunotherapy 2022, Berentsen review)
- Cost-effectiveness and ~80% price-reduction threshold verified against Am J Hematol 2024 (PMID 38733355)
- Prevalent-population size for budget impact verified against PLoS One 2025 (PMID 40570006)
Frequently asked questions
Commission this assessment
AXLRx US Cold Agglutinin Disease Payer & HTA is built for market access, HEOR, and pricing teams navigating high-cost Part B biologic access in a very small rare-disease population. Custom assessment in 72 hours.
Specify indication, payer focus (pricing, PA criteria, cost-effectiveness), and commercial question.
AXLRx analyst confirms payer scope, HTA reference points, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.